- Details
- Description
Trelagliptin is an orally active dipeptidyl peptidase (DPP)-4 inhibitor approved in Japan for the treatment of type 2 diabetes mellitus (T2DM).
Unlike other approved agents of its class, which are usually administered once daily, trelagliptin can be administered once weekly.
Trelagliptin is available as tablet for oral use, containing 50 or 100 mg of free Trelagliptin. The recommended dose is 100 mg of trelagliptin orally once a week for adults.
Gliptins are thought to have cardiovascular protective abilities though the extent of these effects is still being studied. They are also being studied for the ability that this class of drugs has at promoting B-cell survival.
A recent meta-analysis published by Dutta et. al. highlighted the good glycaemic efficacy and safety of this molecule as compared to peer DPP4 inhibitors which have to be taken daily like alogliptin, sitagliptin, linagliptin, teneligliptin, anagliptin or vildagliptin, having an advantage of reducing the monthly pill count from 30 to 4.
